Jonathan Trent on Trabectedin for Soft Tissue Sarcoma

Article

Jonathan Trent, MD, PhD, associate director for clinical research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses the approval of trabectedin to treat patients with soft tissue sarcoma. 

Jonathan Trent, MD, PhD, associate director for clinical research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses the approval of trabectedin (Yondelis) to treat patients with soft tissue sarcoma. 

The FDA approved trabectedin in October 2015 for patients with liposarcoma and leiomyosarcoma who were previously treated with chemotherapy that included an anthracycline. 

The approval was based on a large, randomized study that found trabectedin was superior to dacarbazine chemotherapy in terms of response rates, duration of response, overall survival, and progression-free survival. 

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Related Content
Oncology Nurses Provide Patients an Avenue to Supportive Care

Oncology Nurses Provide Patients an Avenue to Supportive Care

Diana Martins-Welch, MD
November 12th 2019
Article

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.

New Findings Could Change the Everyday Treatment of Patients With Advanced Prostate Cancer

New Findings Could Change the Everyday Treatment of Patients With Advanced Prostate Cancer

Daniel J. George, MD
October 3rd 2019
Article

For patients with advanced prostate cancer, new findings from the CARD trial could change their daily treatment.

Adverse Events of CAR T-Cell Therapy

Adverse Events of CAR T-Cell Therapy

Sattva S. Neelapu, MD
July 28th 2019
Article

It is crucial for nurses to be aware of adverse events that can occur in patients who are receiving CAR T-cell therapy, explained one expert.

Prostate Cancer Diagnoses Decrease With Lenient Screening Recommendations

Prostate Cancer Diagnoses Decrease With Lenient Screening Recommendations

MaryBeth Freeman, MPH
May 8th 2019
Article

After the USPSTF advised against prostate cancer screening for all men, there was a decrease in the incidence of the disease.

Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer

Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer

Hyman B. Muss, MD
March 23rd 2016
Article

Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.

Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making

Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making

Kimberly J. Van Zee, MS, MD, FACS
March 18th 2016
Article

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ductal carcinoma in situ (DCIS).